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AbsTrACT
Introduction The development and implementation of 
national strategic plans is a critical component towards 
successfully addressing antimicrobial resistance (AMR). 
This study aimed to review the scope and analytical 
depth of situation analyses conducted to address 
AMR in human health to inform the development and 
implementation of national strategic plans.
Methods A systematic search of the literature was 
conducted to identify all studies since 2000, that have 
employed a situation analysis to address AMR. The 
included studies are analysed against frameworks 
for strategic analysis, primarily the PESTELI (Political, 
Economic, Sociological, Technological, Ecological, 
Legislative, Industry) framework, to understand 
the depth, scope and utility of current published 
approaches.
results 10 studies were included in the final 
review ranging from single country (6) to regional-
level multicountry studies (4). 8 studies carried out 
documentary review, and 3 of these also included 
stakeholder interviews. 2 studies were based on expert 
opinion with no data collection. No study employed 
the PESTELI framework. Most studies (9) included 
analysis of the political domain and 1 study included 6 
domains of the framework. Technological and industry 
analyses is a notable gap. Facilitators and inhibitors 
within the political and legislative domains were the 
most frequently reported. No facilitators were reported 
in the economic or industry domains but featured 
inhibiting factors including: lack of ring-fenced funding 
for surveillance, perverse financial incentives, cost-
shifting to patients; joint-stock drug company ownership 
complicating regulations.
Conclusion The PESTELI framework provides further 
opportunities to combat AMR using a systematic, strategic 
management approach, rather than a retrospective view. 
Future analysis of existing quantitative data with interviews 
of key strategic and operational stakeholders is needed 
to provide critical insights about where implementation 
efforts should be focussed, and also how to build 
contingency at the strategic level for agile responses to 
macro-level environmental influences.
InTroduCTIon
Antimicrobial resistance (AMR) as a serious 
public health threat is well recognised requiring 
coordination across governments, country 
borders, and health and non-health sectors 
to maintain effectiveness of antimicrobials.1–3 
While AMR occurs naturally, there are multiple 
modifiable drivers which accelerate the emer-
gence and spread of resistant pathogens.4 5 
Wider political, economic, social and epidemi-
ological contextual factors are relevant when 
thinking about drivers to resistance as well as 
solutions.6 7 These wider influences can facilitate 
or impede progress because they have direct and 
indirect effects on individuals (public, patient or 
healthcare professionals), organisations (health-
care and other sectors) and society as a whole.
Key questions
What is already known?
 ► National action plans for addressing antimicrobial 
resistance (AMR) and country-level situation analy-
ses are under way in individual countries and as part 
of learning networks (Global Antibiotic Resistance 
Partnership project) but employ different frame-
works and approaches which may have local rel-
evance but with temporal validity for policy design 
and limited transferability to other contexts.
What are the new findings?
 ► Situation analyses for AMR in human heath have not 
yet employed a strategic management framework 
which is critical for building contingency at the stra-
tegic level for agile responses to macro-level envi-
ronmental influences.
 ► Technological and industry analyses is a notable 
gap.
What do the new findings imply?
 ► Our analysis using a systematic, strategic manage-
ment approach, rather than a retrospective view 
shows where important facilitators and inhibitors 
can be identified and leveraged.
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Figure 1 Study flow diagram. GARP, Global Antibiotic Resistance Partnership.
Strategies and tools to support national-level inter-
ventions include the development and implementation 
of national action plans (NAPs) for AMR, based on best 
available evidence.8 The evidence base for informing 
these management strategies requires multidisciplinary 
approaches including risk assessment,9 10 meta-analysis11 
and cost-effectiveness analysis.12
At the global level, in 2011, the WHO initiated a situa-
tion analysis of country progress in addressing AMR against 
four objectives: (1) Improve awareness and understanding 
of AMR through effective communication, education and 
training. (2) Strengthen the knowledge and evidence base 
through surveillance and research. (3) Reduce the inci-
dence of infection through effective sanitation, hygiene 
and infection prevention measures. (4) Optimise the use 
of antimicrobial medicines in human and animal health.13 
Currently only 19 have a NAP with funding sources identi-
fied, being implemented and with a defined monitoring 
and evaluation process in place. A further 43 have plans 
and processes in place but without funding commitments. 
Fifty-three countries are in the process of developing plans 
and 12 have still not initiated this process. With over 60% 
of countries worldwide at this developmental and planning 
stage, it is critical that rapid dissemination of learning from 
those countries that have progressed is shared. The system-
atic identification of wider influences which could facilitate 
or threaten progress is needed. Additionally, with use of stra-
tegic management approaches, key stakeholders may then 
work proactively to formulate contingent strategies particu-
larly where wider influences carry high levels of uncertainty.
Country-level situation analyses are under way in indi-
vidual countries14 and as part of learning networks (Global 
Antibiotic Resistance Partnership—GARP project) all 
employing different frameworks and approaches which 
may have local relevance but with temporal validity for 
policy design and limited transferability to other contexts.15
In this paper, therefore, we explore the possible contri-
bution to the analysis of the AMR policy context from a 
very different literature stream, namely from the discipline 
of strategic management in management studies. Within 
this very broad field there are many different schools and 
approaches.16 17 An influential and early school which we 
access here can be termed the ‘design and planning’ school 
which seeks to examine the degree of ‘fit’ between an organ-
isation (originally the private firm) and its external envi-
ronment, using formal methods of rational analysis (rather 
than more qualitative methods such as visioning or brain-
storming). One implication of this design and planning 
approach is that if the environment is displaying major shifts, 
then the organisation may need to change too.18 A second 
is that poor fit may well produce poor performance by the 
organisation.
But how can the very broad notion of the ‘external envi-
ronment’ be best conceptualised? The design and planning 
strategic management tradition has produced two important 
and influential tools of analysis (originally for the private 
firm,16 and later for the public agency17), namely SWOT 
analysis (where Strengths and Weaknesses are internal to 
the organisation; but Opportunities and Threats come from 
the external environment), and then the more elaborated 
PESTEL (and later PESTELI (Political, Economic, Socio-
logical, Technological, Ecological, Legislative, Industry)) 
framework which draws attention to the following domains: 
Political factors, Economic influences, Sociological trends, 
Technological innovations, Ecological factors, Legislative 
requirements and then Industry analysis.19
By performing a systematic search of the literature, this 
study aims to identify situation analyses conducted in AMR 
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Table 1 Domains of PESTELI (Political, Economic, Sociological, Technological, Ecological, Legislative, Industry) framework 
covered by the included studies
Study
(author/year) Settings Data collection
PESTELI framework
P E S T E L I
Other 
frameworks
36 Nepal Literature review; grey 
literature; 60 interviews
✓ ✓ ✓ ✓
34 Tanzania Literature review; grey literature ✓ ✓ SWOT 
analysis
35 WHO African 
countries
Literature review ✓ ✓
31 India Documentary review; case 
studies
✓ ✓ ✓ ✓
37 Vietnam Literature review; stakeholder 
and expert opinion
✓ ✓ ✓ ✓ ✓ ✓ ✓
28 Germany Concept piece—no data   ✓ ✓ ✓ ✓
30 Ghana Documentary review; four 
interviews
✓ ✓ ✓ ✓
32 South-East Asia Documentary review ✓ ✓
33 South-East Asia Documentary review ✓ ✓
29 South-East Asia Concept piece—stakeholder 
and expert opinion
✓ ✓
SWOT, Strengths, Weaknesses, Opportunities and Threats.
management in different countries and to assess which 
domains of the PESTELI are included in the extant litera-
ture. By doing so, we assess the depth and scope of previous 
analyses. We also report on the facilitators in addressing 
AMR identified in this previous research as well as the 
inhibitors that have been reported.
MeTHods
We conducted a literature review to identify situation 
analyses in addressing AMR.
study eligibility
Any study published in English since 2000 that has 
performed a situation analysis to address AMR was consid-
ered in this review, in any country(ies) setting(s). The PICO 
(Population, Intervention, Comparison and Outcomes)20 
and SPIDER (sample, phenomenon of interest, design, 
evaluation, research type)21 inclusion and exclusion criteria 
were applied at the review stages. To capture those studies 
that do not mention AMR more generally, but rather 
specific microbes, 13 clinically relevant bacteria (high-
lighted by Public Health England)22 were included in the 
search (eg, Escherichia coli). Studies focussing specifically/
solely on drug resistance in tuberculosis, malaria and HIV 
were excluded. In addition, all of the country-level reports 
published by the GARP network were included (grey liter-
ature).
search strategy and information sources
The methods used in this review are in line with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.23 The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
Protocol (PRISMA-P) checklist was completed as the 
protocol for literature reviews. The search period was 
restricted from January 2000 onwards, because there was 
no policy momentum before this period. The language 
was limited to English. Studies which did not include 
AMR in humans were not included. Ovid Medline and 
Excerpta Medica database (EMBASE), Scopus and 
EconLit, Healthcare Management Information Consor-
tium (HMIC), PsychInfo, and Institute of Electronical 
and Electronics Engineers (IEEE) electronic databases 
were searched. Searches included both controlled vocab-
ulary (predefined subheadings) (eg, Microbials) and 
text words (eg, gram-negative). The search string used is 
provided in online supplementary appendix 1.
study selection
Each title and abstract was independently reviewed by two 
researchers. The full text was independently reviewed by 
two researchers. Any discrepancies (three) were discussed 
and re-examined by a third researcher until agreement was 
reached.
Assessment of study quality and risks of bias
Formal quality appraisal of individual studies included 
was not performed, as this would be beyond the aim of 
this scoping review.24 The aim here was to identify gaps 
in the evidence base and to target topic areas for future 
research.25 26 In addition, use of peer-reviewed publications 
was used as the proxy for good quality.24 In addition, all of 
the country-level reports published by the GARP network, 
though grey literature, were also analysed as this network 
is recognised and cited by the global community for AMR 
policy design and evaluation.27
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Figure 2 Drivers and inhibitors in addressing antimicrobial resistance (AMR) identified in situation analyses.
data extraction and analysis
Data extraction was carried out by three researchers (RA, NJZ 
and EF) and 25% cross-validation between the researchers 
using a standardised data extraction table (Microsoft Excel), 
and then mapped against the PESTELI domains. The 
following information was extracted: study identifiers (title, 
author list, year of publication, journal, digital object identi-
fier (DOI)), study characteristics (objectives, country/region 
setting), methods of data collection. Analysis established the 
scope of the situation analyses in relation to the PESTELI 
and if any other framework had been used. Facilitators and 
inhibitors to addressing AMR were mapped against the 
PESTELI domains. We anticipated descriptive results given 
the qualitative nature of the studies and hence presented 
these in text tables and figures.
Patient and public involvement
This manuscript is part of a wider study, which has one 
public representative. This representative is a member of 
the International Advisory Board, and has commented on 
the early findings of this work in October 2018. This manu-
script being a review, did not require further assessment 
from a patient and public involvement (PPI) perspective. 
The representative will be actively supporting dissemina-
tion of the published work through patient and public 
networks in South Africa, India and the UK.
resulTs
Included studies
A total of 354 studies was identified from the primary 
electronic databases with another three from reference 
list searches. After removal of duplicates and studies in 
tuberculosis, malaria and HIV, a total of 195 records 
remained for screening. Eighteen studies were eligible for 
full-text review and 8 studies were excluded with reasons 
(2 commentary piece only, 6 organisational-level situation 
analysis) yielding a total of 10 studies that fit the inclusion 
criteria. The criteria for study exclusion are provided in 
online supplementary appendix 2. Figure 1 summarises 
the flow of literature searching and screening. Additionally, 
as described above, we included GARP reports published 
in 11 countries.
study characteristics
Of the included studies, six were single-country analysis 
and four regional-level multicountry studies. In terms of 
data collection, one study did not collect new data;28 one 
study used primary data collected through interviews 
with experts;29 one study carried out documentary review 
and interviews;30 three studies carried out a documentary 
review;31–33 two used a review of the literature;34 35 two 
studies reviewed literature and collected primary data 
through interviews with stakeholders.36 37
No study employed the PESTELI framework. Most 
studies (nine) included analysis of the political domain 
and one study included six domains of the framework. 
Technological and industry analyses is a notable gap. Only 
one study employed an established framework (SWOT).28 
Table 1 presents the domains included in each study.
Figure 2 provides details the facilitators and inhibitors 
against the PESTELI framework and the country setting(s).
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Facilitators and inhibitors within the political and legis-
lative domains were the most frequently reported. The 
political domain is featured in each study expect for one.28 
Facilitators and inhibitors within the political and legisla-
tive domains were the most frequently reported. No facili-
tators were reported in the economic or industry domains 
but featured inhibiting factors.
Economic inhibitors were lack of ring-fenced funding 
for surveillance,28 unregulated non-therapeutic antibiotics 
in livestock due to costly alternative hygiene and biosafety 
measures,29 32 33 perverse financial incentives,37 cost-shifting 
to patients.31 Industry inhibitors were identified in only one 
study and reported as complications in regulation arising 
from joint-stock drug company ownership.37
The sociological domain captured education campaigns 
for the public and healthcare professionals as facilitators. 
Low level of confidence and motivation to improve quality 
among healthcare professionals was cited as an inhib-
itor31 and similarly low confidence in laboratory results 
was reported.37 Culture of self-medication and difficulty in 
monitoring this is reported on the public side.37
Among 15 countries that joined the GARP network, 11 
have published a country-level report using situation anal-
ysis for AMR. Table 2 presents the main areas of findings 
included in each GARP country report. The reports have 
followed a structure to cover key areas such as population 
demographics, economic and health systems context, 
burden of diseases in humans and animals, AMR in humans, 
animals and agriculture, and drug regulation and legisla-
tion. There is some variability in terms of which areas are 
investigated in these situation analyses, but all do examine 
the burden of diseases and antibiotic use in humans and 
animals. Estimates of burden of AMR and the influence 
factors associated with the emergence and spread of AMR 
are missing in some countries. Except for Pakistan and 
India, all GARP reports describe the policies for regulating 
antibiotic drugs. Political context is missing in the anal-
yses of nine countries. The heterogeneity of approaches 
to analysis, may be explained by the incremental phases 
of the GARP project. The situation analysis published 
during the first phase of the GARP network (2008–2011) 
conducted documentary review to synthesise secondary 
data from government and healthcare institutes. During 
the second phase (2012–2014), country-level reports have 
been produced using information in published literature. 
During the third phase (2015–current), expert opinion 
and stakeholder interviews have been included in recent 
situation analysis.
The studies identified are all in low and mid-income 
countries (LMICs) barring one study.28
dIsCussIon
Our review shows that the PESTELI framework for stra-
tegic management has not been used for country-level 
analysis for addressing AMR. Some of the domains 
of the framework are included in different studies as 
reported above (figure 2). Analysis of the technological 
and industry domains is a notable gap. Facilitators and 
inhibitors within the political and legislative domains 
were the most frequently reported. No facilitators were 
reported in the economic or industry domains but 
featured inhibiting factors.
Learning from the field of strategic management shows 
that omitting important wider influences when making 
strategic decisions for addressing AMR can result in poli-
cies unaligned with the local landscape and give rise to 
unintended adverse consequences.38
By using a consistent and comprehensive framework 
such as the PESTELI framework, important facilitators 
and inhibitors can be identified and leveraged. Key stake-
holders may then work proactively to formulate contin-
gent strategies particularly where wider influences carry 
high levels of uncertainty. For example, in countries which 
perform well in the economic domain, the factors in the 
political domain can still hinder progress; notably, in Japan, 
five terms of office, seven general elections since 2000 and 
an average length of 1.9 years of office (July 1998 and 
December 2017) may need reliance on strengthening the 
other domains for sustainable solutions.39
Future analysis of existing quantitative data with inter-
views of key strategic and operational stakeholders, from 
each of the domains, is needed to provide critical insights 
about where implementation efforts should be focussed, 
and also how to build contingency at the strategic level for 
agile responses to macro-level environmental influences.
Situation analyses for AMR in human heath have not yet 
employed a strategic management framework which is crit-
ical for building contingency at the strategic level for agile 
responses to macro-level environmental influences.
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